Trust the Power of EYLEA—Proven Results Across All Approved Indications1,2

EYLEA efficacy and safety is backed by 8 pivotal studies evaluating clinical outcomes in over 3000 patients: VIEW 1 and VIEW 2 (Neovascular [Wet] AMD) at 52 and 96 weeks; VISTA and VIVID (DME and DR in patients with DME) at 52 and 100 weeks; PANORAMA (DR) at 24, 52, and 100 weeks; GALILEO and COPERNICUS (MEfCRVO) at 24 weeks; and VIBRANT (MEfBRVO) at 24 weeks.1,2 When starting a patient on EYLEA, consider the body of evidence demonstrating proven results.

EYLEA® (aflibercept) pre-filled syringe and packaging. EYLEA® (aflibercept) pre-filled syringe and packaging.

Empower your EYLEA treatment decisions from the start with RESULTS from the 8 pivotal clinical trials1

  • AMD = Age-related Macular Degeneration
  • DME = Diabetic Macular Edema
  • DR = Diabetic Retinopathy
  • RVO = Retinal Vein Occlusion (includes Branch Retinal Vein Occlusion [BRVO] and Central Retinal Vein Occlusion [CRVO])
EYLEA4U® logo.
EYLEA® (aflibercept) Injection copay card.

Comprehensive Support for Your Patients

From ensuring your eligible patients have access to EYLEA, to helping them navigate the reimbursment, and even guiding you through orders, returns, and more, we're here to help.

EYLEA® (aflibercept) Injection copay card.
In My Eyes by Regeneron logo.

Experience what certain retinal diseases can be like in virtual reality

Retinal disease virtual and augmented reality app.
  • Available on the App Store
  • Android app on Google play

A powerful teaching tool to use with your patients and caregivers, this unique app lets the user experience symptoms of degenerative eye disease, such as diabetic retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

Retinal disease virtual and augmented reality app.
  • Available on the App Store.
  • Android app on Google play.
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. August 2019.
  2. Wykoff CC. Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study. Data presented at: Angiogenesis, Exudation and Degeneration Annual Meeting; February 8, 2020; Miami, FL.